Targeted hepatitis C screening among ex-injection drug users in the community
Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barrier...
Saved in:
Published in | Journal of gastroenterology and hepatology Vol. 29; no. 1; pp. 116 - 120 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Blackwell Publishing Ltd
01.01.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Aim
Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex‐IDUs in the community.
Methods
Patients were recruited through the social worker networks and referrals by fellow ex‐IDUs, and rapid diagnosis was based on point‐of‐care anti‐HCV testing at rehabilitation centers.
Results
From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐HCV positive. The number needed to screen to detect one patient with positive anti‐HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography.
Conclusions
Targeted screening in ex‐IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake. |
---|---|
AbstractList | BACKGROUND AND AIMChronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community.METHODSPatients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers.RESULTSFrom 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography.CONCLUSIONSTargeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake. Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex‐IDUs in the community. Methods Patients were recruited through the social worker networks and referrals by fellow ex‐IDUs, and rapid diagnosis was based on point‐of‐care anti‐HCV testing at rehabilitation centers. Results From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐HCV positive. The number needed to screen to detect one patient with positive anti‐HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Conclusions Targeted screening in ex‐IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake. Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community. Patients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers. From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Targeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake. Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community. Patients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers. From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Targeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake. Abstract Background and Aim Chronic hepatitis C virus ( HCV ) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users ( IDUs ) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the N ew L ife N ew L iver P roject, which provides targeted HCV screening and education for ex‐ IDUs in the community. Methods Patients were recruited through the social worker networks and referrals by fellow ex‐ IDUs , and rapid diagnosis was based on point‐of‐care anti‐ HCV testing at rehabilitation centers. Results From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐ HCV positive. The number needed to screen to detect one patient with positive anti‐ HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA , and liver stiffness measurement by transient elastography. Conclusions Targeted screening in ex‐ IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake. |
Author | Wong, Vincent Wai-Sun Wu, Brian Bing-Ying Cheng, Tsz-Fai Szeto, Kylie Joan-Yi Yiu, Desmond Chi-Him Lai, Camey Wai-Man Wong, Grace Lai-Hung Cheung, David Hui, Alex Yui Chan, Henry Lik-Yuen Yan, Kenneth Kar-Lung Lai, Carol Man-Sze Wu, Stephen Ho-Chun Chung, Cedric Sze-Lai Tsang, Sharon Cheung, Shirley Wing-Yan Chim, Angel Mei-Ling |
Author_xml | – sequence: 1 givenname: Vincent Wai-Sun surname: Wong fullname: Wong, Vincent Wai-Sun organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong – sequence: 2 givenname: Grace Lai-Hung surname: Wong fullname: Wong, Grace Lai-Hung organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong – sequence: 3 givenname: Angel Mei-Ling surname: Chim fullname: Chim, Angel Mei-Ling organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong – sequence: 4 givenname: Tsz-Fai surname: Cheng fullname: Cheng, Tsz-Fai organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 5 givenname: Shirley Wing-Yan surname: Cheung fullname: Cheung, Shirley Wing-Yan organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 6 givenname: Carol Man-Sze surname: Lai fullname: Lai, Carol Man-Sze organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 7 givenname: Kylie Joan-Yi surname: Szeto fullname: Szeto, Kylie Joan-Yi organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 8 givenname: Sharon surname: Tsang fullname: Tsang, Sharon organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 9 givenname: Stephen Ho-Chun surname: Wu fullname: Wu, Stephen Ho-Chun organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong – sequence: 10 givenname: Kenneth Kar-Lung surname: Yan fullname: Yan, Kenneth Kar-Lung organization: Private gastroenterologists, Hong Kong – sequence: 11 givenname: Alex Yui surname: Hui fullname: Hui, Alex Yui organization: Private gastroenterologists, Hong Kong – sequence: 12 givenname: Desmond Chi-Him surname: Yiu fullname: Yiu, Desmond Chi-Him organization: Private gastroenterologists, Hong Kong – sequence: 13 givenname: Brian Bing-Ying surname: Wu fullname: Wu, Brian Bing-Ying organization: Private gastroenterologists, Hong Kong – sequence: 14 givenname: David surname: Cheung fullname: Cheung, David organization: Caritas Lok Heep Club, Hong Kong – sequence: 15 givenname: Cedric Sze-Lai surname: Chung fullname: Chung, Cedric Sze-Lai organization: Caritas Lok Heep Club, Hong Kong – sequence: 16 givenname: Camey Wai-Man surname: Lai fullname: Lai, Camey Wai-Man organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong – sequence: 17 givenname: Henry Lik-Yuen surname: Chan fullname: Chan, Henry Lik-Yuen email: hlychan@cuhk.edu.hk organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24033786$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkE1vEzEQQC1URNPCgT9Q-VgO29rrj9k9VoGkoAJSVcTR8tqTxGnWm9q7Ivn3LKTtrVLnMHN58w7vhBzFLiIhHzm74ONcrperC14Kpd6QCZeSFRykPiITVnFV1ILXx-Qk5zVjTDJQ78hxKZkQUOkJ-X5n0xJ79HSFW9uHPmQ6pdklxBjiktq2GzfuihDX6PrQRerTsKRDxpRpiLRfIXVd2w4x9Pv35O3CbjJ-eLyn5Nfsy930urj5Of86vbopnNSlKngDCj1XrIHSe9c0HB1gg3UjnKyVYLAAaEDUznqpEcoKPTiPtgItLVhxSs4P3m3qHgbMvWlDdrjZ2IjdkA2Xta5qppV6DcoAatBsRD8dUJe6nBMuzDaF1qa94cz8C23G0OZ_6JE9e9QOTYv-mXwqOwKXB-BP2OD-ZZP5Nr9-UhaHj5B73D1_2HRvNAhQ5vePuVFy9pnN-K25FX8BJ4WYTw |
CitedBy_id | crossref_primary_10_1016_j_drugpo_2017_05_019 crossref_primary_10_1038_s41575_018_0026_5 crossref_primary_10_1186_s12876_020_01277_0 crossref_primary_10_3748_wjg_v27_i16_1728 crossref_primary_10_1093_ofid_ofw065 crossref_primary_10_3748_wjg_v22_i33_7604 crossref_primary_10_1016_j_drugalcdep_2014_12_027 crossref_primary_10_9778_cmajo_20140024 crossref_primary_10_1007_s12072_015_9630_4 crossref_primary_10_1111_jgh_14003 crossref_primary_10_1111_jvh_12760 crossref_primary_10_3109_14659891_2014_1000986 crossref_primary_10_1111_jgh_14622 crossref_primary_10_1016_j_drugpo_2015_07_003 crossref_primary_10_1111_liv_13949 crossref_primary_10_1111_liv_13926 crossref_primary_10_1016_j_antiviral_2014_01_002 crossref_primary_10_1080_14737159_2017_1400385 crossref_primary_10_1111_apt_12745 crossref_primary_10_1016_j_drugpo_2018_08_011 crossref_primary_10_1038_nrgastro_2017_106 crossref_primary_10_1016_S2468_1253_17_30075_4 crossref_primary_10_1093_ofid_ofv101 crossref_primary_10_1111_jgh_12890 crossref_primary_10_35772_ghm_2021_01049 crossref_primary_10_1007_s11606_015_3209_6 crossref_primary_10_1007_s10461_015_1074_2 |
Cites_doi | 10.1016/j.cgh.2008.02.038 10.1136/gut.2006.111302 10.7326/0003-4819-156-4-201202210-00004 10.1056/NEJMoa1014463 10.1056/NEJMoa1013086 10.1056/NEJMoa1104430 10.1056/NEJMoa1208953 10.1016/S0140-6736(10)61497-3 10.1056/NEJMra1213651 10.7326/0003-4819-144-10-200605160-00010 10.1056/NEJMoa1010494 10.7326/0003-4819-157-8-201210160-00006 10.1056/NEJMoa1012912 10.1056/NEJMoa0908014 10.1056/NEJMoa1214853 10.1111/jgh.12041 10.7326/0003-4819-149-6-200809160-00006 10.1016/S0140-6736(11)61097-0 10.1016/j.jhep.2011.02.023 10.1056/NEJMp1302973 10.1053/jhep.2001.25882 10.1007/s10620-010-1412-1 10.1056/NEJMoa1009482 10.1001/jama.280.6.547 10.7326/0003-4819-157-9-201211060-00529 10.7326/0003-4819-158-5-201303050-00005 10.1002/hep.22759 10.1086/427449 10.1038/ajg.2013.50 10.1056/NEJMoa1214854 |
ContentType | Journal Article |
Copyright | 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
Copyright_xml | – notice: 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd – notice: 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 H94 |
DOI | 10.1111/jgh.12355 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Virology and AIDS Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1746 |
EndPage | 120 |
ExternalDocumentID | 10_1111_jgh_12355 24033786 JGH12355 ark_67375_WNG_54FD0F1R_R |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Hong Kong |
GeographicLocations_xml | – name: Hong Kong |
GrantInformation_xml | – fundername: Food and Health Bureau of the Government of the Hong Kong SAR funderid: 6902849 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABEML ABHUG ABJNI ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHEFC AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DTERQ DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KMS LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AITYG HGLYW OIG CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 H94 |
ID | FETCH-LOGICAL-c4625-1b75ed150b72ddcbb1ec7ebe9b3c495307f77b739cad46e728ed7cdea8764a7a3 |
IEDL.DBID | DR2 |
ISSN | 0815-9319 |
IngestDate | Fri Aug 16 01:39:22 EDT 2024 Fri Aug 16 05:04:42 EDT 2024 Fri Aug 23 00:55:36 EDT 2024 Sat Sep 28 07:53:15 EDT 2024 Sat Aug 24 00:55:15 EDT 2024 Wed Jan 17 05:02:36 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | patient compliance interferons opioid-related disorders elasticity liver cirrhosis |
Language | English |
License | 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4625-1b75ed150b72ddcbb1ec7ebe9b3c495307f77b739cad46e728ed7cdea8764a7a3 |
Notes | ark:/67375/WNG-54FD0F1R-R ArticleID:JGH12355 istex:F65930BB5201A8DBBB0E277F2C7DAAB55843A3FD Food and Health Bureau of the Government of the Hong Kong SAR - No. 6902849 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 24033786 |
PQID | 1490779760 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_1496890655 proquest_miscellaneous_1490779760 crossref_primary_10_1111_jgh_12355 pubmed_primary_24033786 wiley_primary_10_1111_jgh_12355_JGH12355 istex_primary_ark_67375_WNG_54FD0F1R_R |
PublicationCentury | 2000 |
PublicationDate | January 2014 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: January 2014 |
PublicationDecade | 2010 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia |
PublicationTitle | Journal of gastroenterology and hepatology |
PublicationTitleAlternate | J Gastroenterol Hepatol |
PublicationYear | 2014 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010; 376: 1441-1442. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann. Intern. Med. 2012; 157: 558-566. Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013; 368: 1867-1877. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012; 156: 271-278. Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J. Gastroenterol. Hepatol. 2013; 28: 707-716. Wong GL, Wong VW, Choi PC et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035. Yan KK, Wong GL, Wong VW, Chan HL. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. Dig. Dis. Sci. 2010; 55: 3541-3547. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-264. Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 2008; 149: 399-403. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005; 40 (Suppl. 5): S336-338. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-224. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-193. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 2013; 368: 1907-1917. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416. Spaulding AC, Weinbaum CM, Lau DT et al. A framework for management of hepatitis C in prisons. Ann. Intern. Med. 2006; 144: 762-769. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878-1887. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 2013; 158: 329-337. Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am. J. Gastroenterol. 2013; 108: 981-989. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann. Intern. Med. 2012; 157: 817-822. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N. Engl. J. Med. 2013; 368: 1859-1861. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428. Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303. 2010; 55 2011; 378 1998; 280 2012; 156 2013; 28 2012; 157 2012; 366 2013; 108 2013; 368 2010; 376 2005; 40 2013; 158 2011; 55 2010; 362 2008; 149 2008; 6 2013 2001; 34 2007; 56 2009; 49 2011; 365 2006; 144 2011; 364 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_11_1 e_1_2_6_12_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_29_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – volume: 55 start-page: 3541 year: 2010 end-page: 3547 article-title: Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital publication-title: Dig. Dis. Sci. – volume: 368 start-page: 1878 year: 2013 end-page: 1887 article-title: Sofosbuvir for previously untreated chronic hepatitis C infection publication-title: N. Engl. J. Med. – volume: 364 start-page: 2417 year: 2011 end-page: 2428 article-title: Telaprevir for retreatment of HCV infection publication-title: N. Engl. J. Med. – volume: 40 start-page: S336 issue: Suppl. 5 year: 2005 end-page: 338 article-title: Follow‐up studies of treatment for hepatitis C virus infection among injection drug users publication-title: Clin. Infect. Dis. – volume: 55 start-page: 245 year: 2011 end-page: 264 article-title: EASL Clinical Practice Guidelines: management of hepatitis C virus infection publication-title: J. Hepatol. – volume: 56 start-page: 968 year: 2007 end-page: 973 article-title: Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease publication-title: Gut – volume: 156 start-page: 271 year: 2012 end-page: 278 article-title: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 publication-title: Ann. Intern. Med. – volume: 368 start-page: 1867 year: 2013 end-page: 1877 article-title: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options publication-title: N. Engl. J. Med. – volume: 366 start-page: 216 year: 2012 end-page: 224 article-title: Preliminary study of two antiviral agents for hepatitis C genotype 1 publication-title: N. Engl. J. Med. – volume: 364 start-page: 2405 year: 2011 end-page: 2416 article-title: Telaprevir for previously untreated chronic hepatitis C virus infection publication-title: N. Engl. J. Med. – volume: 362 start-page: 1292 year: 2010 end-page: 1303 article-title: Telaprevir for previously treated chronic HCV infection publication-title: N. Engl. J. Med. – volume: 34 start-page: 188 year: 2001 end-page: 193 article-title: Treatment of hepatitis C infection in injection drug users publication-title: Hepatology – volume: 6 start-page: 1027 year: 2008 end-page: 1035 article-title: Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases publication-title: Clin. Gastroenterol. Hepatol. – volume: 368 start-page: 34 year: 2013 end-page: 44 article-title: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C publication-title: N. Engl. J. Med. – volume: 365 start-page: 1014 year: 2011 end-page: 1024 article-title: Response‐guided telaprevir combination treatment for hepatitis C virus infection publication-title: N. Engl. J. Med. – volume: 28 start-page: 707 year: 2013 end-page: 716 article-title: Assessing the cost‐effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia publication-title: J. Gastroenterol. Hepatol. – volume: 368 start-page: 1859 year: 2013 end-page: 1861 article-title: Hepatitis C in the United States publication-title: N. Engl. J. Med. – volume: 158 start-page: 329 year: 2013 end-page: 337 article-title: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies publication-title: Ann. Intern. Med. – volume: 280 start-page: 547 year: 1998 end-page: 549 article-title: Barriers to use of free antiretroviral therapy in injection drug users publication-title: JAMA – volume: 149 start-page: 399 year: 2008 end-page: 403 article-title: Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C publication-title: Ann. Intern. Med. – volume: 108 start-page: 981 year: 2013 end-page: 989 article-title: Birth cohort screening for chronic hepatitis during colonoscopy appointments publication-title: Am. J. Gastroenterol. – volume: 368 start-page: 1907 year: 2013 end-page: 1917 article-title: Current and future therapies for hepatitis C virus infection publication-title: N. Engl. J. Med. – volume: 376 start-page: 1441 year: 2010 end-page: 1442 article-title: Curing hepatitis C with pills: a step toward global control publication-title: Lancet – volume: 378 start-page: 571 year: 2011 end-page: 583 article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews publication-title: Lancet – volume: 364 start-page: 1195 year: 2011 end-page: 1206 article-title: Boceprevir for untreated chronic HCV genotype 1 infection publication-title: N. Engl. J. Med. – volume: 157 start-page: 817 year: 2012 end-page: 822 article-title: Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention publication-title: Ann. Intern. Med. – volume: 157 start-page: 558 year: 2012 end-page: 566 article-title: Accuracy of rapid and point‐of‐care screening tests for hepatitis C: a systematic review and meta‐analysis publication-title: Ann. Intern. Med. – volume: 49 start-page: 1335 year: 2009 end-page: 1374 article-title: American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update publication-title: Hepatology – volume: 144 start-page: 762 year: 2006 end-page: 769 article-title: A framework for management of hepatitis C in prisons publication-title: Ann. Intern. Med. – volume: 364 start-page: 1207 year: 2011 end-page: 1217 article-title: Boceprevir for previously treated chronic HCV genotype 1 infection publication-title: N. Engl. J. Med. – year: 2013 – ident: e_1_2_6_15_1 doi: 10.1016/j.cgh.2008.02.038 – ident: e_1_2_6_16_1 doi: 10.1136/gut.2006.111302 – ident: e_1_2_6_2_1 doi: 10.7326/0003-4819-156-4-201202210-00004 – ident: e_1_2_6_25_1 doi: 10.1056/NEJMoa1014463 – ident: e_1_2_6_28_1 doi: 10.1056/NEJMoa1013086 – ident: e_1_2_6_29_1 doi: 10.1056/NEJMoa1104430 – ident: e_1_2_6_30_1 doi: 10.1056/NEJMoa1208953 – ident: e_1_2_6_14_1 doi: 10.1016/S0140-6736(10)61497-3 – ident: e_1_2_6_3_1 doi: 10.1056/NEJMra1213651 – ident: e_1_2_6_20_1 doi: 10.7326/0003-4819-144-10-200605160-00010 – ident: e_1_2_6_24_1 doi: 10.1056/NEJMoa1010494 – ident: e_1_2_6_21_1 doi: 10.7326/0003-4819-157-8-201210160-00006 – ident: e_1_2_6_23_1 doi: 10.1056/NEJMoa1012912 – ident: e_1_2_6_17_1 – ident: e_1_2_6_26_1 doi: 10.1056/NEJMoa0908014 – ident: e_1_2_6_32_1 doi: 10.1056/NEJMoa1214853 – ident: e_1_2_6_10_1 doi: 10.1111/jgh.12041 – ident: e_1_2_6_4_1 doi: 10.7326/0003-4819-149-6-200809160-00006 – ident: e_1_2_6_7_1 doi: 10.1016/S0140-6736(11)61097-0 – ident: e_1_2_6_12_1 doi: 10.1016/j.jhep.2011.02.023 – ident: e_1_2_6_6_1 doi: 10.1056/NEJMp1302973 – ident: e_1_2_6_8_1 doi: 10.1053/jhep.2001.25882 – ident: e_1_2_6_22_1 doi: 10.1007/s10620-010-1412-1 – ident: e_1_2_6_27_1 doi: 10.1056/NEJMoa1009482 – ident: e_1_2_6_13_1 doi: 10.1001/jama.280.6.547 – ident: e_1_2_6_18_1 doi: 10.7326/0003-4819-157-9-201211060-00529 – ident: e_1_2_6_5_1 doi: 10.7326/0003-4819-158-5-201303050-00005 – ident: e_1_2_6_11_1 doi: 10.1002/hep.22759 – ident: e_1_2_6_9_1 doi: 10.1086/427449 – ident: e_1_2_6_19_1 doi: 10.1038/ajg.2013.50 – ident: e_1_2_6_31_1 doi: 10.1056/NEJMoa1214854 |
SSID | ssj0004075 |
Score | 2.2709913 |
Snippet | Background and Aim
Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly... Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among... Abstract Background and Aim Chronic hepatitis C virus ( HCV ) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is... BACKGROUND AND AIMChronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 116 |
SubjectTerms | Alanine Transaminase Biomarkers Community Health Services Community Networks Drug Users - statistics & numerical data elasticity Elasticity Imaging Techniques Female Follow-Up Studies Hepacivirus - genetics Hepacivirus - immunology Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - epidemiology Hepatitis C - prevention & control Hepatitis C virus Hong Kong - epidemiology Humans interferons liver cirrhosis Male Mass Screening - methods Middle Aged opioid-related disorders patient compliance Patient Education as Topic Point-of-Care Systems RNA, Viral Severity of Illness Index |
Title | Targeted hepatitis C screening among ex-injection drug users in the community |
URI | https://api.istex.fr/ark:/67375/WNG-54FD0F1R-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.12355 https://www.ncbi.nlm.nih.gov/pubmed/24033786 https://search.proquest.com/docview/1490779760 https://search.proquest.com/docview/1496890655 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB6Kgnjx_agvooh42bLtPrKLJ6m2RVChWPQgLMkmfVjYSruF6smf4G_0lzjJPrSiIt5ymCXZzCTzTTLzBeCwIhm3fNszhO-2DZt53MCGNEI0lrJQmceaSunyym207Is7564AJ1ktTMIPkR-4qZWh92u1wBkffV7knW5JFXqqAnNFpKcAUfODOspOSHbR4zmGj3aWsgrpLJ7syylfNKumdfId0JzGrdrx1BbhPhtykm_SL41jXgqfv7A5_vOflmAhBaTkNLGgZSjIaAXmLtMr91W4vtG54lKQrlTZ13FvRKoENxsMgNHtEf1aEZGTt5fXXvSgE7siIobjDlHnHyPSiwhiTBImhSjx0xq0auc31YaRvsKA-sLgyChz6kiBuJHTihAh52UZUlS9z61QJaeatE0pp5YfMmG7klY8KWgoJMN91maUWeswEw0iuQnEE0y9ESlcicCFWSZDWY8Kx_NdjHNcpwgHmT6Cx4RsI8iDlE430FNThCOtqVyCDfsqO406we1VPXDs2plZKzeDZhH2M1UGuGbURQiL5GA8wnDHNylFIGb-KuN6PgI07HAjsYO8R8VhaFHPLcKx1ubPgw0u6g3d2Pq76DbMIyqzk3OeHZiJh2O5i8gn5nvaxN8BRSf93Q |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NThsxEB4FIhUuhZa_lJ-6VVVx2WiTXa93JS4ICCFNUikKKhdk2WuTBKSlSjYS5cQj8Iw8CWNvNgUECHHzYVb2emY839ifxwA_qlpIL_JDR0XBmeOLUDrY0E6MxlJRhnlsSym12kH92G-c0JMC7OR3YbL6ENMNN-MZdr02Dm42pB96ea9fNjc96QwU0d2pTag6_4tH-VmZXYx51InQ0iZ1hSyPJ__0UTQqmom9eg5qPkauNvTUFuA0H3TGOLkoj1NZjq-f1HN8718twscJJiW7mRF9goJOPsOH1uTUfQl-dy1dXCvS14aAnQ5GZI_geoM5MEY-Yh8sIvrq7uZ2kJxbbldC1HDcI2YLZEQGCUGYSeLsLkr6bxmOawfdvbozeYgBVYb5kVORjGqF0FGyqlKxlBUdM9R-JL3Y8FNddsaYZF4UC-UHmlVDrVistMCl1hdMeCswm1wmeg1IqIR5JlIFGrGL8FyBsiFTNIwCTHUCWoLvuUL436zeBp_mKb0-t1NTgp9WVVMJMbwwBDVG-Z_2Iad-bd-tVTq8U4JvuS45uo05CxGJvhyPMOOJXMYQi7mvygRhhBgNO1zNDGHaoylj6LEwKMG2VefLg-WNw7ptfHm76FeYq3dbTd48av9ah3kEaX627bMBs-lwrDcRCKVyy9r7PS-XAg4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkBCXQnm0C7Q1CFVcsspuHDtRT4htWF4LWoHKoZJlx94HSAHtZiXaU38Cv5FfwtjZLAWVCvXmw0R2PDOeb-zPY4CtupEqiGnk6Zh1PCoj5WHDeCkaS01b5rErpXTcYs1zenARXkzB1_IuTFEfYrLhZj3DrdfWwW90508n7_aq9qJn-AZmKAvq1qQb7cfaUbSososhL_RiNLRxWSFH4yk_fRKMZuy83v4NaT4Fri7yJPPwoxxzQTi5qo5yVU1_PSvn-J8_tQBvx4iU7BQm9A6mTLYIs8fjM_clODlzZHGjSc9Y-nXeH5JdgqsNZsAY94h7roiY2_vfd_3s0jG7MqIHoy6xGyBD0s8IgkySFjdR8p_LcJ58O9tteuNnGFBhmB15NcVDoxE4Kl7XOlWqZlKOuo9VkFp2qs87nCsexKnUlBlej4zmqTYSF1oquQxWYDq7zswHIJGW9pFIzQwiFxn4EmUjrsMoZpjosLACm6U-xE1RbUNMspRuT7ipqcAXp6mJhBxcWXoaD8X31p4IadLwk1pbtCuwUapSoNPYkxCZmevREPOd2OcckZj_TxkWxYjQsMP3hR1MerRFDAMesQpsO22-PFhxsNd0jdXXi36G2dNGIo72W4drMIcIjRZ7PuswnQ9G5iOioFx9ctb-ACy1AL0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+hepatitis+C+screening+among+ex-injection+drug+users+in+the+community&rft.jtitle=Journal+of+gastroenterology+and+hepatology&rft.au=Wong%2C+Vincent+Wai-Sun&rft.au=Wong%2C+Grace+Lai-Hung&rft.au=Chim%2C+Angel+Mei-Ling&rft.au=Cheng%2C+Tsz-Fai&rft.date=2014-01-01&rft.eissn=1440-1746&rft.volume=29&rft.issue=1&rft.spage=116&rft_id=info:doi/10.1111%2Fjgh.12355&rft_id=info%3Apmid%2F24033786&rft.externalDocID=24033786 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0815-9319&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0815-9319&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0815-9319&client=summon |